Kamal Hamed

Chief Medical Officer

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Kamal Hamed is the Chief Medical Officer at Spero Therapeutics in the United States. His research primarily focuses on pharmacokinetics, antibiotic efficacy, and mycobacterial infections, as evidenced by his recent publications. Some of his notable articles include studies on the pharmacokinetics of SPR206 and evaluations of factors predictive of efficacy in complicated urinary tract infections.

Articles (11)

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (3)

Nicholas Turner

Assistant Professor

Duke University School of Medicine

UNITED STATES

View details

Marc Engelhardt

SWITZERLAND

View details

Christopher Lyon

Tulane University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kamal Hamed

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Evaluation of Factors Predictive of Efficacy Among Patients With Complicated Urinary Tract Infection and/or Acute Pyelonephritis

Serum Cell-Free DNA-based Detection of Mycobacterium avium Complex Infection

Intrapulmonary pharmacokinetics of SPR719 following oral administration of SPR720 to healthy volunteers

Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies

Ceftobiprole for Treatment of Complicated <i>Staphylococcus aureus</i> Bacteremia.

Safety and pharmacokinetics of SPR206 in subjects with varying degrees of renal impairment

A narrative review of nontuberculous mycobacterial pulmonary disease: microbiology, epidemiology, diagnosis, and management challenges

Nontuberculous mycobacterial pulmonary disease and the potential role of SPR720

Impact of antibiotic pharmacokinetics in urine on recurrent bacteriuria following treatment of complicated urinary tract infections

Pharmacokinetics of SPR206 in Plasma, Pulmonary Epithelial Lining Fluid, and Alveolar Macrophages following Intravenous Administration to Healthy Adult Subjects

Plain language summary: use of isavuconazole in Chinese patients with an invasive fungal disease.

Collaborators (3)

Nicholas Turner

Marc Engelhardt

Christopher Lyon

Make your next move.